Predictive Biomarkers of Overall Survival in Patients with Metastatic Renal Cell Carcinoma Treated with IFNα ± Bevacizumab: Results from CALGB 90206 (Alliance).

Andrew B Nixon Susan HalabiYingmiao LiuMark D StarrJohn C BradyIvo ShterevBin Luo Herbert I Hurwitz Phillip G FebboBrian I RiniHimisha BeltranEric J SmallMichael J Morris Daniel J George

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2022)

IL6 and HGF are potential predictive biomarkers of OS benefit from BEV + IFN in patients with mRCC. The model based on key biological and clinical factors demonstrated predictive efficacy for OS. These markers warrant further validation in future anti-VEGF and immunotherapy in mRCC trials. See related commentaries by Mishkin and Kohn, p. 2722 and George and Bertagnolli, p. 2725.

Keyphrases

metastatic renal cell carcinoma
immune response
dendritic cells
vascular endothelial growth factor
endothelial cells
current status
density functional theory
risk assessment
metastatic colorectal cancer
free survival
newly diagnosed
molecular dynamics